Where Will AbbVie Be in 5 Years? [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
A lot has changed for AbbVie (NYSE: ABBV) over the past five years. Notably, the biotech company's Humira, once its biggest growth driver and the world's best-selling drug, lost patent exclusivity in the U.S. in 2023. Despite that setback, AbbVie has produced solid returns over the last half a decade. But can the drugmaker maintain that momentum through 2031? Let's find out how things might unfold for AbbVie over the next five years. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Image source: Getty Images. Same growth drivers and new products AbbVie has performed relatively well despite the Humira patent cliff, thanks to two other immunology medicines: Skyrizi and Rinvoq. These products should drive solid top-line growth through the end of the decade and beyond. Neither will lose patent protection by 20
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Viokace (AbbVie) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
- AbbVie (ABBV) had its "buy" rating reaffirmed by Guggenheim.MarketBeat
- RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages [Yahoo! Finance]Yahoo! Finance
- Josh Brown: Biotech growth stocks immune to disruption risk [Yahoo! Finance]Yahoo! Finance
- Market Downturn: 2 Stocks to Buy and Hold Through Any Storm [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 3/11/26 - Form 4/A
- 3/9/26 - Form PRE
- 3/6/26 - Form 4
- ABBV's page on the SEC website